These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9400632)

  • 1. Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors.
    Rusconi S; Berlusconi A; Papagno L; Colombo MC; De Maddalena C; Riva A; Bagnarelli P; Balotta C; Galli M
    Clin Immunol Immunopathol; 1997 Dec; 85(3):320-3. PubMed ID: 9400632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of in vitro anti-gp160 antibody production is a correlate of nonprogression among HIV type 1-infected individuals.
    Rusconi S; Santambrogio S; Di Marco A; Colombo MC; Citterio P; Adorni F; Galli M
    AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1341-3. PubMed ID: 9788675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    Montefiori DC; Pantaleo G; Fink LM; Zhou JT; Zhou JY; Bilska M; Miralles GD; Fauci AS
    J Infect Dis; 1996 Jan; 173(1):60-7. PubMed ID: 8537683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1-infected patients with envelope-specific lymphoproliferation or long-term nonprogression lack antibodies suppressing glycoprotein 120 antigen presentation.
    Chien PC; Chen D; Chen PD; Tuen M; Cohen S; Migueles SA; Connors M; Rosenberg E; Malhotra U; Gonzalez C; Hioe CE
    J Infect Dis; 2004 Mar; 189(5):852-61. PubMed ID: 14976603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.
    Baum LL; Cassutt KJ; Knigge K; Khattri R; Margolick J; Rinaldo C; Kleeberger CA; Nishanian P; Henrard DR; Phair J
    J Immunol; 1996 Sep; 157(5):2168-73. PubMed ID: 8757343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.
    Zhang YJ; Fracasso C; Fiore JR; Björndal A; Angarano G; Gringeri A; Fenyö EM
    J Infect Dis; 1997 Nov; 176(5):1180-7. PubMed ID: 9359717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
    Hogervorst E; Jurriaans S; de Wolf F; van Wijk A; Wiersma A; Valk M; Roos M; van Gemen B; Coutinho R; Miedema F
    J Infect Dis; 1995 Apr; 171(4):811-21. PubMed ID: 7706807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro anti-HIV-1 antibody production in subjects in different stages of HIV-1 infection.
    Rusconi S; Riva A; Meroni L; Zehender G; Cocchi F; Scapellato L; Galli M
    Clin Exp Immunol; 1995 Oct; 102(1):26-30. PubMed ID: 7554395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies.
    Khouri YF; McIntosh K; Cavacini L; Posner M; Pagano M; Tuomala R; Marasco WA
    J Clin Invest; 1995 Feb; 95(2):732-7. PubMed ID: 7860754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antibody production (IVAP) in the follow-up of pediatric human immunodeficiency virus type 1-infected patients.
    Rusconi S; Riva A; Cocchi F; Massironi E; Tornaghi R; de Maddalena C; de Pasquale MP; Galli M
    Pediatr AIDS HIV Infect; 1997 Apr; 8(2):127-9. PubMed ID: 11361779
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between Nef-specific CD8 T-cell responses and disease progression in HIV-1 subtype B infection.
    Jiao Y; Li TS; Xie J; Han Y; Qiu ZF; Zuo LY; Mourez T; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(19):1609-15. PubMed ID: 17042973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection.
    Lefrère JJ; Morand-Joubert L; Mariotti M; Bludau H; Burghoffer B; Petit JC; Roudot-Thoraval F
    Blood; 1997 Aug; 90(3):1133-40. PubMed ID: 9242545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable biological and molecular determinants in HIV type 1-infected long-term nonprogressors and recently infected individuals.
    Balotta C; Bagnarelli P; Riva C; Valenza A; Antinori S; Colombo MC; Sampaolesi R; Violin M; de Pasquale MP; Moroni M; Clementi M; Galli M
    AIDS Res Hum Retroviruses; 1997 Mar; 13(4):337-41. PubMed ID: 9071433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
    Jurriaans S; Van Gemen B; Weverling GJ; Van Strijp D; Nara P; Coutinho R; Koot M; Schuitemaker H; Goudsmit J
    Virology; 1994 Oct; 204(1):223-33. PubMed ID: 7916514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].
    Meshcheriakova DV; Andreev SM; Sidorova MV; Vafina MG; Az'muko AA; Petrukhina AO; Khaitov RM
    Vestn Ross Akad Med Nauk; 1992; (9-10):47-52. PubMed ID: 1283721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of infection with human immunodeficiency virus type 1 before seroconversion: correlation with clinical symptoms and outcome.
    Phair JP; Margolick JB; Jacobson LP; Phillips J; Rinaldo C; Kaslow R; Chu C; Giorgi JV; Henrard D
    J Infect Dis; 1997 Apr; 175(4):959-62. PubMed ID: 9086159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.
    Pastori C; Weiser B; Barassi C; Uberti-Foppa C; Ghezzi S; Longhi R; Calori G; Burger H; Kemal K; Poli G; Lazzarin A; Lopalco L
    Blood; 2006 Jun; 107(12):4825-33. PubMed ID: 16522810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-F(ab')2 antibody in HIV type 1 infection: relationship to hypergammaglobulinemia and to antibody specific to the V3 loop region of glycoprotein 120.
    Morrison SA; Pearson SL; Steigbigel RT
    AIDS Res Hum Retroviruses; 1998 Apr; 14(6):491-8. PubMed ID: 9566551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.